MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2025016877

Медицинская библиотека · Blood advances · 2026

Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis.

Ibrahim Sara, Burgos-Mansilla Barbara, Roldan Yetiani, Oliveros Maria Jose, Bhogal Gurleen, Bravo-Soto Gonzalo, Bagherianlemraski Mobina, Movahed Hamed, Gutierrez-Arias Ruvistay, Mulazzani Francesca, Khorrami Taj Tanin, Hadeiy Seyed Kaveh, Qureshi Manahil, Chowdhury Saifur R, Couban Rachel, Artz Andrew, Fletcher Luke, Gilberto Linda, Mattison Ryan, Sekeres Mikkael A, Brignardello-Petersen Romina

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

This systematic review summarizes the evidence informing 2 recommendations from the updated American Society of Hematology guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, comparing conventional induction and postremission therapy vs hypomethylating agents (HMA)- or low-dose cytarabine (LDAC)-based strategies, with or without venetoclax. We searched Ovid MEDLINE and Embase, and Cochrane CENTRAL through February 2024, and monitored these databases for new studies throughout November 2024. We included randomized controlled trials (RCTs) and nonrandomized studies (NRS). Reviewers screened studies, extracted data, assessed risk of bias, conducted random-effects meta-analyses, and rated certainty of evidence using GRADE (grading of recommendations, assessment, development, and evaluation). We included 21 studies (3 RCTs, 18 NRS). Compared with HMA- or LDAC-based monotherapy, conventional 7+3-type remission induction therapy may reduce mortality at longest follow-up (risk ratio [RR], 0.94; 95% confidence interval [CI], 0.85-1.04; low certainty), increase complete remission rates (odds ratio, 1.75; 95% CI, 1.25-2.38; high certainty), and may reduce recurrence at longest follow-up (RR, 0.81; 95% CI, 0.64-1.04; low certainty). Conventional therapies probably increase most severe toxicities (moderate certainty). Compared with HMA or LDAC combined with venetoclax, very low certainty evidence suggests that conventional therapy may reduce 1-year mortality (RR, 0.72; 95% CI, 0.60-0.87), increase allogeneic transplant rates (RR, 2.28; 95% CI, 1.70-3.06), result in no important differences in complete remission or recurrence, and have variable effects on severe toxicities. Conventional therapy may have benefits over HMA or LDAC alone; however, compared with HMA or LDAC plus venetoclax, the evidence remains of very low certainty.

Для цитирования: Ibrahim Sara, Burgos-Mansilla Barbara, Roldan Yetiani, Oliveros Maria Jose, Bhogal Gurleen, Bravo-Soto Gonzalo, Bagherianlemraski Mobina, Movahed Hamed, Gutierrez-Arias Ruvistay, Mulazzani Francesca, Khorrami Taj Tanin, Hadeiy Seyed Kaveh, Qureshi Manahil, Chowdhury Saifur R, Couban Rachel, Artz Andrew, Fletcher Luke, Gilberto Linda, Mattison Ryan, Sekeres Mikkael A, Brignardello-Petersen Romina. Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis.. Blood advances. 2026. DOI: 10.1182/bloodadvances.2025016877.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.